Join the Diabetes, Type 2 group to help and get support from people like you.
Diabetes, Type 2 News (Page 24)
Related terms: Noninsulin-dependent Diabetes, Type 2 Diabetes, Diabetes, Type 2
FDA Medwatch Alert: SGLT2 inhibitors: Drug Safety Communication - FDA Warns Medicines May Result in a Serious Condition of Too Much Acid in the Blood
ISSUE: FDA is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of blood...
Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo
PARIS, Feb. 25, 2015 – Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal...
FDA Approves Glyxambi (empagliflozin and linagliptin) for Type 2 Diabetes
RIDGEFIELD, Conn. and INDIANAPOLIS, Feb. 2, 2015 – The U.S. Food and Drug Administration (FDA) has approved Glyxambi (empagliflozin/linagliptin) tablets, from Boehringer Ingelheim Pharmaceuticals, I...
FDA Approves Xigduo XR (dapagliflozin and metformin hydrochloride) for Type 2 Diabetes
WILMINGTON, Del., October 30, 2014 – AstraZeneca today announced that the U.S. Food and Drug Administration has approved once-daily Xigduo XR (dapagliflozin and metformin hydrochloride...
FDA Approves Trulicity (dulaglutide) for Type 2 Diabetes
September 18, 2014 – The U.S. Food and Drug Administration today approved Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with...
FDA Approves Invokamet (canagliflozin/metformin) for Type 2 Diabetes
RARITAN, N.J., August 8, 2014 – Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved Invokamet, a fixed dose therapy combining canagliflozin and m...
FDA Approves Jardiance (empagliflozin) to Treat Type 2 Diabetes
August 1, 2014 – The U.S. Food and Drug Administration today approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2...
FDA Approves Afrezza to Treat Diabetes
June 27, 2014 – The U.S. Food and Drug Administration today approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes...
FDA Medwatch Alert: Olmesartan: Drug Safety Communication - FDA Review Finds Cardiovascular Risks for Diabetics Not Conclusive
Includes: Benicar, Benicar HCT, Azor, Tribenzor, and Generics [Posted 06/24/2014] ISSUE: FDA has completed its safety review and has found no clear evidence of increased cardiovascular risks...
FDA Approves Tanzeum (albiglutide) to Treat Type 2 Diabetes
April 15, 2014 – The U.S. Food and Drug Administration today approved Tanzeum (albiglutide) subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with type 2...
FDA Approves Bydureon Pen for Once-Weekly Treatment of Adults with Type 2 Diabetes
Monday March 3, 2014 – AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon Pen (exenatide extended-release for injectable suspension) 2 mg as an...
FDA Medwatch Alert: Saxagliptin (marketed as Onglyza and Kombiglyze XR): Drug Safety Communication - FDA to Review Heart Failure Risk
ISSUE: FDA has requested clinical trial data from the manufacturer of saxagliptin to investigate a possible association between use of the type 2 diabetes drug and heart failure. FDAs request...
FDA Approves Farxiga to Treat Type 2 Diabetes
January 8, 2014 – The U.S. Food and Drug Administration today approved Farxiga (dapagliflozin) tablets to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes. ...
FDA Medwatch Alert: Rosiglitazone-containing Diabetes Medicines: Drug Safety Communication - Removal of Some Prescribing and Dispensing Restrictions
including Avandia, Avandamet, Avandaryl, and generics [Posted 11/25/2013] ISSUE: FDA has determined that recent data for rosiglitazone-containing drugs, such as Avandia, Avandamet, Avandaryl, and ...
FDA Medwatch Alert: Diabetes Treatments: FDA Alerts of Illegal Sales - Undeclared Ingredients
ISSUE: FDA is taking action to remove from the market illegal products, including some labeled as dietary supplements, that claim to mitigate, treat, cure or prevent diabetes and related...
Further information
Related condition support groups
Related drug support groups
metformin, Ozempic, Mounjaro, Victoza, Lantus, semaglutide, Trulicity, glipizide, Rybelsus, view more... tirzepatide, Jardiance, liraglutide, Lantus Solostar, Humalog, Farxiga, Novolog, Janumet, insulin glargine, Januvia, Bydureon, insulin lispro, Tresiba, dulaglutide, Levemir, insulin degludec, Invokana, glimepiride, Glucophage, Humulin N